PT - JOURNAL ARTICLE AU - Lu, Jing AU - Plessis, Louis du AU - Liu, Zhe AU - Hill, Verity AU - Kang, Min AU - Lin, Huifang AU - Sun, Jiufeng AU - François, Sarah AU - Kraemer, Moritz U G AU - Faria, Nuno R AU - McCrone, John T AU - Peng, Jingju AU - Xiong, Qianlin AU - Yuan, Runyu AU - Zeng, Lilian AU - Zhou, Pingping AU - Liang, Chuming AU - Yi, Lina AU - Liu, Jun AU - Xiao, Jianpeng AU - Hu, Jianxiong AU - Liu, Tao AU - Ma, Wenjun AU - Li, Wei AU - Su, Juan AU - Zheng, Huanying AU - Peng, Bo AU - Fang, Shisong AU - Su, Wenzhe AU - Li, Kuibiao AU - Sun, Ruilin AU - bai, Ru AU - Tang, Xi AU - Liang, Minfeng AU - Quick, Josh AU - Song, Tie AU - Rambaut, Andrew AU - Loman, Nick AU - Raghwani, Jayna AU - Pybus, Oliver G AU - Ke, Changwen TI - Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China AID - 10.1101/2020.04.01.20047076 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.01.20047076 4099 - http://medrxiv.org/content/early/2020/04/04/2020.04.01.20047076.short 4100 - http://medrxiv.org/content/early/2020/04/04/2020.04.01.20047076.full AB - COVID-19 is caused by the SARS-CoV-2 coronavirus and was first reported in central China in December 2019. Extensive molecular surveillance in Guangdong, China’s most populous province, during early 2020 resulted in 1,388 reported RNA positive cases from 1.6 million tests. In order to understand the molecular epidemiology and genetic diversity of SARS-CoV-2 in China we generated 53 genomes from infected individuals in Guangdong using a combination of metagenomic sequencing and tiling amplicon approaches. Combined epidemiological and phylogenetic analyses indicate multiple independent introductions to Guangdong, although phylogenetic clustering is uncertain due to low virus genetic variation early in the pandemic. Our results illustrate how the timing, size and duration of putative local transmission chains were constrained by national travel restrictions and by the province’s large-scale intensive surveillance and intervention measures. Despite these successes, COVID-19 surveillance in Guangdong is still required as the number of cases imported from other countries is increasing.Highlights1.6 million molecular diagnostic tests identified 1,388 SARS-CoV-2 infections in Guangdong Province, China, by 19th March 2020Virus genomes can be recovered using a variety of sequencing approaches from a range of patient samples.Genomic analyses reveal multiple virus importations into Guangdong Province, resulting in genetically distinct clusters that require careful interpretation.Large-scale epidemiological surveillance and intervention measures were effective in interrupting community transmission in GuangdongCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Guangdong Provincial Novel Coronavirus Scientific and Technological Project (2020111107001), Science and Technology Planning Project of Guangdong (2018B020207006). OP, MUGK and LdP were supported by the Oxford Martin School. V.H. is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grant number BB/M010996/1). NRF acknowledges funding from a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z) and from a Medical Research Council and FAPESP award (MR/S0195/1). This work was supported by the Wellcome Trust ARTIC network.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences data have been submitted to the public database (GISAID). https://platform.gisaid.org/epi3/frontend